Valneva plunges then recovers: what’s really happening with the stock and the VLA2001 vaccine?
If you've been following this French biotech for the past decade, you know that roller-coaster rides are part and parcel of the journey. But what happened to Valneva this week would make even the most seasoned investors wince. The stock abruptly broke below €4.35, flirting with €3.89 before showing some signs of a rebound. These kinds of swings always create a frenzy among retail investors. So, what's behind this latest about-face?
Solid financial results, but a fickle market mood
Let's put things into perspective. Based on the financial results announced a few days ago, the company's fundamentals are sound. Revenues are there, cash flow is steady, and the development of vaccine candidates is progressing. So why the drop? Because in the stock market, especially for a company of this size, the devil is in the expectations. The market was probably hoping for a more aggressive outlook or bigger news on the progress of the much-anticipated Lyme disease vaccine.
But here, we're talking about science, not magic. Thomas Lingelbach, the CEO, reiterates this every time he speaks: developing preventive vaccines against infectious diseases isn't something that happens overnight. VLA15 (the name of their Lyme disease candidate) is likely the most closely watched pipeline in the industry because if it succeeds, it will be the first modern-day "golden goose" for this disease. But until it gets the final green light, the stock price remains under pressure.
VLA2001, the COVID vaccine that changed the game... and expectations
Let's not forget where we came from. With VLA2001, Valneva proved it could compete with the big players. This inactivated virus vaccine, used notably within strict protocols, was a much-needed lifeline. For those following the regulatory side, the Generic Protocol for ECDC Studies of COVID-19 Vaccine Effectiveness Against Confirmed SARS-CoV-2 Using Healthcare Worker Cohorts: Version 3.0 remains an important benchmark for assessing real-world effectiveness.
But today, the market has a short memory. The COVID era is behind us, and investors don't want to hear about legacy vaccines anymore. They want something new, something disruptive. And right now, Valneva finds itself in a bit of a lull, caught between the end of the COVID euphoria and the still-maturing pipeline for its Lyme candidate. This is often the phase where stock prices suffer the most, because traders dislike a vacuum. They prefer blockbuster quarterly announcements over silent waiting periods.
Reasons to be optimistic (or not) going forward
So, what should you do if you hold Valneva in your portfolio or are eyeing the stock? Here are a few key points to consider:
- Cash and visibility: The company has secured funding and partnerships. It's not going to disappear tomorrow. The financial results confirm this: there's enough runway to reach the next major milestones.
- The Lyme timeline: VLA15 is the primary catalyst. The next data readouts, if positive, could literally send the stock soaring. It's a binary outcome, but with enormous potential.
- Thomas Lingelbach's experience: He's no novice. He has weathered storms far more severe than this slight market chill. His strategy, focused on developing preventive vaccines, remains consistent.
In the stock market, emotions are often amplified with this type of stock. The drop below €4.35 triggered stop losses and automatic selling, mechanically amplifying the move. That's classic. What's more interesting is seeing if the stock manages to stabilise above this psychological level in the coming sessions. If it does, the technical rebound could be just as sharp as the fall.
Let's not kid ourselves, betting on Valneva today means betting on the biotech of tomorrow, with all the risks and rewards that entails. But those who held on through the uncertain phases with VLA2001 will remember: when the science delivers, the market always catches on eventually.